| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00781-2321-06 | 00781-2321 | Aprepitant | Aprepitant | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 27, 2016 | In Use | |
| 55513-0021-04 | 55513-0021 | Darbepoetin alfa | Aranesp | 40.0 ug/.4mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 14, 2006 | In Use | ||
| 00310-0625-60 | 00310-0625 | SELUMETINIB | KOSELUGO | 25.0 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | Apr 16, 2020 | In Use | |
| 16571-0817-41 | 16571-0817 | Temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 4, 2022 | In Use | |
| 55648-0634-01 | 55648-0634 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
| 70860-0201-20 | 70860-0201 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Mar 15, 2017 | In Use | |
| 00115-1438-10 | 00115-1438 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 20, 2015 | In Use | |
| 00517-0440-01 | 00517-0440 | ESTRADIOL VALERATE | ESTRADIOL VALERATE | 40.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | Mar 1, 2020 | In Use | ||
| 63187-0002-10 | 63187-0002 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 1, 2018 | In Use | |
| 70954-0652-20 | 70954-0652 | Finasteride and Tadalafil | Finasteride and Tadalafil | 5.0 mg/1, 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 24, 2025 | In Use | |
| 68180-0801-36 | 68180-0801 | lapatinib | Lapatinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Sep 29, 2020 | In Use | |
| 63187-0693-15 | 63187-0693 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 1, 2016 | In Use | |
| 16714-0963-01 | 16714-0963 | Abiraterone Acetate | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | May 19, 2020 | In Use | |
| 50090-2345-09 | 50090-2345 | Methotrexate, Methotrexate sodium | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Apr 8, 2016 | In Use | |
| 59676-0302-00 | 59676-0302 | Erythropoietin | Procrit | 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 8, 2011 | In Use | ||
| 63850-0128-02 | 63850-0128 | Everolimus | Everolimus | 2.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 30, 2025 | In Use | |
| 68727-0745-01 | 68727-0745 | (daunorubicin and cytarabine) liposome | Vyxeos | 100.0 mg/20mL, 44.0 mg/20mL | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | Intravenous | Aug 3, 2017 | In Use | |
| 10019-0939-01 | 10019-0939 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | May 21, 2008 | In Use | |
| 50742-0366-30 | 50742-0366 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 27, 2023 | In Use | |
| 70518-3837-00 | 70518-3837 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 18, 2023 | In Use | |
| 71335-1926-02 | 71335-1926 | Prednisone | PREDNISONE | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 11, 2021 | In Use | |
| 51655-0699-53 | 51655-0699 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 2, 2021 | In Use | |
| 83076-1025-03 | 83076-1025 | Ensartinib | ENSACOVE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK, ROS1, MET | Oral | Apr 30, 2025 | In Use | |
| 47335-0715-81 | 47335-0715 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 25, 2022 | No Longer Used | |
| 21695-0360-01 | 21695-0360 | Triamcinolone Acetonide | Kenalog-40 | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intramuscular | Jun 1, 2009 | In Use |
Found 11888 results — Export these results
Home